Plain-English translation of NCT06232772 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson's Disease research guide →Researchers are testing a new diagnostic method that analyzes skin samples and body fluids to detect a protein called alpha-synuclein, which builds up abnormally in Parkinson's disease. Currently, diagnosing Parkinson's accurately can be difficult and takes a long time, leading to missed or delayed diagnoses in about 20% of cases. This study aims to see if this simple, minimally invasive test can help doctors identify the disease much earlier.
Parkinson's disease and related conditions are hard to diagnose in their early stages because symptoms overlap with other diseases. Right now, the only way to confirm these diagnoses with certainty is through brain tissue biopsy, which is invasive and rarely done. This trial exists to create a better, easier alternative that could catch these diseases sooner, when treatment is most effective.
You likely qualify if…
You likely don't qualify if…
If you participate, researchers will collect a tiny skin sample (about 1mm) and body fluid samples like blood or cerebrospinal fluid. These samples will be tested using specialized laboratory methods to measure alpha-synuclein levels. You will likely visit the research center once or a few times for sample collection, and the procedure is minimally invasive—much simpler than a brain biopsy. The study involves about 600 participants total across multiple medical centers.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China